HLA
ARQT icon

Hamilton Lane Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Hamilton Lane Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52,347
Closed -$1.01M – 72
2022
Q1 		$1.01M Hold
52,347
– – 0.23% 40
2021
Q4 		$1.09M Hold
52,347
– – 0.14% 54
2021
Q3 		$1.25M Sell
52,347
-48,859
-48% -$1.11M 0.21% 46
2021
Q2 		$2.76M Buy
+101,206
New +$2.85M 0.86% 30

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hamilton Lane Advisors's ARQT Position: Q2 2022 in Review

Hamilton Lane Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q2 2022, closing a stake of 52,347 shares — an estimated $1.01M sold.

Hamilton Lane Advisors first reported a position in ARQT in Q2 2021 and held it in 4 quarters. The position peaked at $2.76M in Q2 2021. 115 funds tracked by Wall St. Rank hold ARQT as of Q2 2022.

  • Hamilton Lane Advisors reported no remaining Arcutis Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Hamilton Lane Advisors sold 52,347 Arcutis Biotherapeutics shares in Q2 2022, an estimated $1.01M.
  • Hamilton Lane Advisors first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 4 quarters.
  • Hamilton Lane Advisors's Arcutis Biotherapeutics position peaked at $2.76M in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2022.

Based on Hamilton Lane Advisors's 13F filing for Q2 2022, filed 28 Jul 2022.